BioXcel Therapeutics, Inc. Operating Lease Cost
BioXcel Therapeutics, Inc. (BTAI) reported Operating Lease Cost of $108.00 thousand for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2020-08-14
- BioXcel Therapeutics, Inc. operating lease, cost for the quarter ending 2020-06-30 was $54.00K, a 0.00% change year-over-year.
- BioXcel Therapeutics, Inc. operating lease, cost for the quarter ending 2020-03-31 was $54.00K, a 145.45% increase year-over-year.
- BioXcel Therapeutics, Inc. operating lease, cost for the quarter ending 2019-12-31 was $46.00K.
- BioXcel Therapeutics, Inc. operating lease, cost for the quarter ending 2019-09-30 was $33.00K.
- BioXcel Therapeutics, Inc. operating lease, cost for fiscal 2019 was $155.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2020-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $108.00K 10-Q · filed 2020-08-14 | $154.00K derived: sum of 3 quarters · filed 2020-08-14 | $187.00K derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2020-03-31 | $54.00K 10-Q · filed 2020-05-12 | $100.00K derived: sum of 2 quarters · filed 2020-05-12 | $133.00K derived: sum of 3 quarters · filed 2020-05-12 | $187.00K derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $79.00K derived: sum of 2 quarters · filed 2020-03-09 | $133.00K derived: sum of 3 quarters · filed 2020-08-14 | $155.00K 10-K · filed 2020-03-09 | ||
| 2019-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $87.00K derived: sum of 2 quarters · filed 2020-08-14 | $109.00K 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $76.00K 10-Q · filed 2020-08-14 | $62.00K 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $22.00K 10-Q · filed 2020-05-12 | $16.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |